Claris Lifesciences surges on receiving USFDA approval for Tobramycin injection

07 Jul 2016 Evaluate

Claris Lifesciences is currently trading at Rs. 235.00, up by 17.80 points or 8.20% from its previous closing of Rs. 217.20 on the BSE.

The scrip opened at Rs. 230.00 and has touched a high and low of Rs. 246.05 and Rs. 230.00 respectively. So far 1,15,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 266.00 on 30-Jul-2015 and a 52 week low of Rs. 126.10 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 246.05 and Rs. 212.50 respectively. The current market cap of the company is Rs. 1,282.34 crore.

The promoters holding in the company stood at 60.99%, while Institutions and Non-Institutions held 21.37% and 17.64% respectively.

Claris Lifesciences has received the United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Tobramycin Injection USP, 80mg/2mL and 1,200mg/30mL multiple dose vials.

Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract. The estimated market size in the US is $6 million, as the product is currently in shortage list of the US drug regulator.

With this approval, Claris now has 14 approvals and 24 under approval ANDAs. The company expects more product approvals during the year, which will allow it to continue its growth in the US market.


Peers
Company Name CMP
Adani Enterprises 3379.00
Redington 205.90
Amrapali Industries 14.42
Rashi Peripheral 333.00
Compuage Infocom 4.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.